Last edition
News about "BAY 3670549"
Bayer Initiates Phase 2 Trial of Investigational GIRK4 Inhibitor for Atrial Fibrillation
Bayer has initiated a global Phase 2 trial of BAY 3670549, an investigational GIRK4 inhibitor being evaluated as a potential treatment for atrial fibrillation and rapid cardioversion.
BAY 3670549 | 10/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members